10.12
-0.23 (-2.22%)
| Previous Close | 10.35 |
| Open | 10.57 |
| Volume | 800,405 |
| Avg. Volume (3M) | 1,267,727 |
| Market Cap | 597,851,776 |
| Price / Book | 2.09 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.77 |
| Total Debt/Equity (MRQ) | 0.33% |
| Current Ratio (MRQ) | 11.62 |
| Operating Cash Flow (TTM) | -150.21 M |
| Levered Free Cash Flow (TTM) | -87.13 M |
| Return on Assets (TTM) | -25.38% |
| Return on Equity (TTM) | -36.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cullinan Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.20 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.55% |
| % Held by Institutions | 116.27% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Wedbush, 235.97%) | Buy |
| Median | 31.50 (211.27%) | |
| Low | 27.00 (HC Wainwright & Co., 166.80%) | Buy |
| Average | 31.00 (206.32%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 12.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Feb 2026 | 33.00 (226.09%) | Buy | 12.19 |
| Guggenheim | 02 Feb 2026 | 30.00 (196.44%) | Buy | 12.71 |
| HC Wainwright & Co. | 08 Jan 2026 | 27.00 (166.80%) | Buy | 11.14 |
| Wedbush | 09 Dec 2025 | 34.00 (235.97%) | Buy | 12.36 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AHMED NADIM | - | 13.96 | -29,896 | -416,460 |
| FENTON MARY KAY | 12.44 | 13.65 | 64,352 | 795,217 |
| JONES JEFFREY ALAN | - | 13.96 | -9,564 | -133,389 |
| MICHAELSON JENNIFER | 12.44 | 13.98 | 38,625 | 453,564 |
| SUMER JACQUELYN L | - | 13.96 | -7,343 | -102,465 |
| Aggregate Net Quantity | 56,174 | |||
| Aggregate Net Value ($) | 596,468 | |||
| Aggregate Avg. Buy ($) | 12.44 | |||
| Aggregate Avg. Sell ($) | 13.94 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MICHAELSON JENNIFER | Officer | 25 Feb 2026 | Automatic sell (-) | 1,780 | 14.36 | 25,561 |
| SUMER JACQUELYN L | Officer | 24 Feb 2026 | Sell (-) | 3,601 | 14.27 | 51,386 |
| JONES JEFFREY ALAN | Officer | 24 Feb 2026 | Sell (-) | 4,582 | 14.27 | 65,385 |
| AHMED NADIM | Officer | 24 Feb 2026 | Sell (-) | 13,515 | 14.27 | 192,859 |
| MICHAELSON JENNIFER | Officer | 24 Feb 2026 | Sell (-) | 3,601 | 14.27 | 51,386 |
| MICHAELSON JENNIFER | Officer | 23 Feb 2026 | Automatic sell (-) | 1,752 | 13.99 | 24,510 |
| SUMER JACQUELYN L | Officer | 20 Feb 2026 | Sell (-) | 3,742 | 13.65 | 51,078 |
| MICHAELSON JENNIFER | Officer | 20 Feb 2026 | Sell (-) | 3,742 | 13.65 | 51,078 |
| MICHAELSON JENNIFER | Officer | 20 Feb 2026 | Automatic sell (-) | 8,000 | 13.65 | 109,200 |
| MICHAELSON JENNIFER | Officer | 20 Feb 2026 | Option execute | 8,000 | - | - |
| AHMED NADIM | Officer | 20 Feb 2026 | Sell (-) | 16,381 | 13.65 | 223,601 |
| FENTON MARY KAY | Officer | 20 Feb 2026 | Sell (-) | 4,398 | 13.65 | 60,033 |
| JONES JEFFREY ALAN | Officer | 20 Feb 2026 | Sell (-) | 4,982 | 13.65 | 68,004 |
| MICHAELSON JENNIFER | Officer | 18 Feb 2026 | Acquired (+) | 57,500 | 12.44 | 715,300 |
| FENTON MARY KAY | Officer | 18 Feb 2026 | Acquired (+) | 68,750 | 12.44 | 855,250 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | Announcement | Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones |
| 08 Dec 2025 | Announcement | Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |